NCT04238689View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of TB31F

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 14, 2020

Primary Completion Date

March 4, 2021

Study Completion Date

March 4, 2021

Conditions
Malaria,Falciparum
Interventions
BIOLOGICAL

TB31F

Monoclonal antibody

Trial Locations (1)

6525 GA

Radboud University Medical Center, Nijmegen

All Listed Sponsors
collaborator

The PATH Malaria Vaccine Initiative (MVI)

OTHER

lead

Radboud University Medical Center

OTHER

NCT04238689 - Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of TB31F | Biotech Hunter | Biotech Hunter